In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Positive Panel Recommendation For Contrave Could Change Obesity Drug Game

Executive Summary

FDA's Endocrinologic and Metabolic Drugs Advisory Committee's surprise vote recommending Orexigen Therapeutics’ obesity drug Contrave (naltrexone SR/bupropion SR) for approval has boosted hopes that at least some of the current generation of obesity drugs in development may reach the market – just not in the order that everyone had expected.
Advertisement

Related Content

Losing The Battle Of The Bulge: FDA Holds Up Orexigen's Contrave
Losing The Battle Of The Bulge: FDA Holds Up Orexigen's Contrave
Losing The Battle Of The Bulge: FDA Holds Up Orexigen's Contrave
Panel Continues To Push For Obesity CV Guidance As It Backs Contrave Approval
Panel Continues To Push For Obesity CV Guidance As It Backs Contrave Approval
The Skinny On The Obesity Drug Advisory Committees: A Look At The Panelists' Votes
Orexigen Offers Robust Contrave Risk Plan To Monitor For Safety Concerns
Arena and Vivus Take Divergent Paths To CRL Response
Vivus' Qnexa Gets "Complete Response" Letter From FDA
Lorqess' Slight Efficacy, Potential Safety Issues Leave Arena On The Hot Seat At Advisory Panel

Topics

Advertisement
UsernamePublicRestriction

Register

PS052939

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel